The Bulletin
The Times


.

OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the 2025

  • Written by PR Newswire

CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity

CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs

Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant high-grade serous ovarian cancer (HGSOC) without CDH6...

hacklink esim balkanSahabetuk casinos not on gamstopGamStopcanlı casino sitelerijojobetviagra 100 mg fiyat